Neoplasm Metastasis Clinical Trial
Official title:
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases
Verified date | May 2013 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Whole Brain Radiation Therapy (WBRT) in treating patients with brain metastases.
Status | Completed |
Enrollment | 80 |
Est. completion date | March 2013 |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
Inclusion Criteria: - Age is greater than or equal to 18 years. - Histologically or cytologically confirmed non-CNS primary solid malignancy. - Pathologically or radiographically confirmed metastatic disease in the brain. Subjects with non-measurable lesions, including leptomeningeal carcinomatosis, are eligible. - WBRT is clinically indicated, with the exception of prophylactic treatment. - Karnofsky Performance Status (KPS) greater than or equal to a score of 70. - Adequate hematology, renal and hepatic function. - Both men and women of childbearing potential must agree to use adequate contraception (one of the following listed below) prior to study entry, for the duration of study participation and up to 2 months following completion of protocol therapy. - Total abstinence from sexual intercourse (minimum one complete menstrual cycle) - A vasectomized partner * Hormonal contraceptives (oral, parenteral or transdermal) for at least 3 months prior to study drug administration - Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring with spermicidal jellies or cream) - Subject is capable of understanding and complying with parameters as outlined in the protocol. - Subject or the subject's legally acceptable representative has voluntarily signed and dated the informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures. Exclusion Criteria: - Brain metastases secondary to germ cell tumor or lymphoma malignancy. - Primary central nervous system (CNS) neoplasm. - Prior or concurrent administration of the following therapies or treatments: - Prior treatment with WBRT - SRS performed less than 14 days prior to WBRT D1, or is scheduled to occur within 30 days of the last WBRT session - Last dose of chemotherapy, immunotherapy, biologic therapy, or investigational therapy was less than 14 days prior to WBRT D1. Bisphosphonates, hormone modification therapy, and trastuzumab are permitted without restriction - Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment. - Known seizure disorder (status epileptics) that is uncontrolled, or seizures occurring greater than or equal to 3 times a week over the past month. - If female, subject is pregnant or breast-feeding. - Clinically significant and uncontrolled major cardiac, respiratory, renal, hepatic, gastrointestinal, hematologic or neurological/psychiatric disease or disorder, including but not limited to: - Active uncontrolled infection - Symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia - Any other illness condition(s) that could exacerbate potential toxicities, confound safety assessments, require excluded therapy for management, or limit compliance with study requirements - Unable to swallow and retain oral medications. - Known contraindication to enhanced MRI and CT, including but not limited to: - Presence of metal objects within the body such as a cardiac pacemaker, implanted cardiac defibrillator, brain aneurysm clips, cochlear implant, ocular foreign body, or shrapnel - History of immediate or delayed hypersensitivity reaction or other contraindication to contrast agents including but not limited to gadolinium and iodine - Previous enrollment in this study or another study involving the investigation of ABT-888, with the exception of receiving a single dose of study drug. - Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive ABT-888 and/or WBRT. |
Country | Name | City | State |
---|---|---|---|
Canada | Site Reference ID/Investigator# 18542 | Toronto | |
Puerto Rico | Site Reference ID/Investigator# 46322 | Ponce | |
United States | Site Reference ID/Investigator# 8334 | Atlanta | Georgia |
United States | Site Reference ID/Investigator# 7180 | Baltimore | Maryland |
United States | Site Reference ID/Investigator# 52462 | Chicago | Illinois |
United States | Site Reference ID/Investigator# 19021 | Detroit | Michigan |
United States | Site Reference ID/Investigator# 24483 | Kansas City | Kansas |
United States | Site Reference ID/Investigator# 6653 | Madison | Wisconsin |
United States | Site Reference ID/Investigator# 6344 | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
AbbVie (prior sponsor, Abbott) |
United States, Canada, Puerto Rico,
Mehta MP, Wang D, Wang F, Kleinberg L, Brade A, Robins HI, Turaka A, Leahy T, Medina D, Xiong H, Mostafa NM, Dunbar M, Zhu M, Qian J, Holen K, Giranda V, Curran WJ. Veliparib in combination with whole brain radiation therapy in patients with brain metasta — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determine the maximum tolerated dose of ABT-888 in combination with whole brain radiation therapy | ABT-888 will be dose escalated until the largest dose is reached that is felt to be safe based on safety information from all subjects. | ||
Secondary | Safety Assessment Physical and Neurological Exam | be performed at all study visits, final and follow-up visit | ||
Secondary | Safety Assessment Mini-Mental State Examination | be performed at all study visits, final and follow-up visit | ||
Secondary | Safety Assessment Laboratory testing | Chemistry and Hematology labs will be collected | be performed at all study visits, final and follow-up visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03775980 -
CIRSE Emprint Microwave Ablation Registry
|
||
Completed |
NCT01114958 -
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
|
Phase 1 | |
Terminated |
NCT03986593 -
Cryoablation of Bone Metastases From Endocrine Tumors
|
N/A | |
Active, not recruiting |
NCT04458259 -
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
|
Phase 1 | |
Completed |
NCT01218542 -
Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc
|
N/A | |
Not yet recruiting |
NCT03175146 -
A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely
|
N/A | |
Active, not recruiting |
NCT02395224 -
A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway
|
||
Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
Recruiting |
NCT01960829 -
Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study
|
Phase 2 | |
Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
Terminated |
NCT01846429 -
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
|
Phase 1 | |
Recruiting |
NCT01564810 -
Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
|
Phase 4 | |
Completed |
NCT00375245 -
Rapamycin With Grapefruit Juice for Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00207116 -
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
|
Phase 1 | |
Completed |
NCT00232726 -
Clinical Study of Previously Untreated Patients With Malignant Melanoma
|
Phase 2 | |
Completed |
NCT00172003 -
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
|
Phase 4 | |
Completed |
NCT00207103 -
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 |